Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis

Diagnostic Molecular Pathology

Volumn 13, Issue 4, 2004, Pages 241-246

  Chu, Quyen D ^a   Hurd, Thelma C ^a   Harvey, Shashi ^a,c   Martinick, Maisie ^a   Markus, Gabor ^b   Tan, Dongfeng ^b   Gibbs, John F ^a   Loree, Thom ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Biomarkers prognosis; Immunohistochemistry; In situ hybridization; Tall cell variant; Thyroid cancer; Urinary plasminogen activator

Indexed keywords

MESSENGER RNA; UROKINASE;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICLE; THYROID GLAND; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; RNA, MESSENGER; RNA, NEOPLASM; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 9244231807     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pdm.0000137100.26010.64     Document Type: Article

References (30)

1. American Association of Clinical Endocrinologists. AACE Clinical Practice Guidelines for the Management of Thyroid Carcinoma. Endocr Pract. 1997;3:60-71.
2. Loree TR. Therapeutic implications of prognostic factors in differentiated carcinoma of the thyroid gland. Semin Surg Oncol. 1995;11:246-255.
3. Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cells variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988;12:22-27.
4. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Comparison with the common form of papillary carcinoma by DNA and morphometric analysis. Cleve Clin Q. 1976;43:207-215.
5. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;17:3226-3235.
6. Gharib H, Goellner HR. Fine needle aspiration biopsy of the thyroid: An appraisal. Ann Intern Med. 1993;118:282-289.
7. Causo D. Fine needle aspiration in the management of thyroid nodules. Endocrinologist. 1991;1:194-202.
8. Chen H, Zeiger MA, Clark DP, et al. Papillary thyroid cancer: Can operative management be solely based on fin needle aspiration? J Am Coll Surg. 1997;184:602-610.
9. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 1997;72:1-22.
10. Schmitt M, Wilhelm OG, Reuning U, et al. The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinolysis Proteolysis. 2000;14:114.
11. Ghosh S, Ellerbroer SM, Wu Y, et al. Tumor cell-mediated proteolysis: Regulatory mechanisms and functional consequences. Fibrinolysis Proteolysis. 2000;14:87.
12. Packman KS, Demeure MJ, Doffek KM, et al. Increased plasminogen activator and type IV collagenase activity in invasive follicular carcinoma cells. Surgery. 1995;118:1011-1017.
13. Ito Y, Takeda T, Kobayashi T, et al. Plasminogen activation system is active even in thyroid tumors: An immunohistochemical study. Anticancer Res. 1996;16:81-90.
14. LiVolsi VA. Surgical pathology of the thyroid. Vol. 5, Philadelphia, WB Saunders, 1990.
15. Harvey SR, Sait SN, Xu Y, et al. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol. 1999;155:1115-1120.
16. Harvey SR, Hurd TC, Markus G, et al. Evaluation of urinary plasminogen activator, its receptor, matrixmetalloproteinase-9 and von Willebrand Factor in pancreatic cancer. Clin Cancer Res. 2003;9:4935-4943.
17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-173.
18. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
19. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI (Y) protein in the diagnosis of thyroid tumors: HMGI (Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 1998;58:4193-4198.
20. Arscott PL, Stokes T, Myc A, et al. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab. 1999;84:4246-4252.
21. Satta MA, Nanni S, Della Casa S, et al. A Molecular biology of thyroid neoplasms. Rays. 2000;25:151-161.
22. Hoang-Vu C, Boltze C, Gimm O, et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol. 2002;21:265-272.
23. Herrmann ME, LiVolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710-713.
24. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044-15049.
25. Wasenius V-M, Hemmer S, Kettunen E, et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: A cDNA and tissue microarray study. Clin Cancer Res. 2003;9:68-75.
26. Sandrini F, Matyakhina L, Sarlis NJ, et al. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A) A tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer. 2002;35:182-192.
27. Liu RT, Huang CC, You HL, et al. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene. 2002;21:4830-4837.
28. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636-643.
29. Nielsen BS, Sehested M, Duun S, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest. 2001;81:1485.
30. Zanetti A, Stoppacciaro A, Marzullo A, et al. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol. 1998;3:287-291.